Gilead Sciences, Inc. (NASDAQ:GILD) Shares Acquired by Oppenheimer Asset Management Inc.

Oppenheimer Asset Management Inc. grew its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 20.5% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 183,224 shares of the biopharmaceutical company's stock after purchasing an additional 31,148 shares during the period. Oppenheimer Asset Management Inc.'s holdings in Gilead Sciences were worth $12,571,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Institute for Wealth Management LLC. grew its holdings in Gilead Sciences by 1.9% during the second quarter. Institute for Wealth Management LLC. now owns 7,551 shares of the biopharmaceutical company's stock worth $518,000 after acquiring an additional 142 shares during the period. First Affirmative Financial Network grew its holdings in Gilead Sciences by 3.5% during the first quarter. First Affirmative Financial Network now owns 4,342 shares of the biopharmaceutical company's stock worth $318,000 after acquiring an additional 147 shares during the period. Rathbones Group PLC boosted its position in Gilead Sciences by 3.7% during the fourth quarter. Rathbones Group PLC now owns 4,185 shares of the biopharmaceutical company's stock worth $339,000 after purchasing an additional 150 shares in the last quarter. MCF Advisors LLC boosted its position in Gilead Sciences by 2.1% during the first quarter. MCF Advisors LLC now owns 7,348 shares of the biopharmaceutical company's stock worth $538,000 after purchasing an additional 152 shares in the last quarter. Finally, Westside Investment Management Inc. boosted its position in Gilead Sciences by 0.6% during the second quarter. Westside Investment Management Inc. now owns 26,526 shares of the biopharmaceutical company's stock worth $1,826,000 after purchasing an additional 152 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company's stock.

Insider Activity

In other news, insider Johanna Mercier sold 29,357 shares of the stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $83.78, for a total value of $2,459,529.46. Following the completion of the sale, the insider now owns 78,127 shares in the company, valued at $6,545,480.06. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other Gilead Sciences news, insider Johanna Mercier sold 29,357 shares of the firm's stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the completion of the sale, the insider now owns 78,127 shares in the company, valued at approximately $6,545,480.06. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $68.63, for a total value of $137,260.00. Following the completion of the transaction, the insider now owns 96,380 shares of the company's stock, valued at approximately $6,614,559.40. The disclosure for this sale can be found here. Over the last quarter, insiders sold 36,847 shares of company stock worth $3,002,940. 0.16% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of analysts have commented on GILD shares. Robert W. Baird reiterated a "neutral" rating and set a $80.00 target price on shares of Gilead Sciences in a research report on Thursday, June 20th. Royal Bank of Canada upped their price objective on Gilead Sciences from $72.00 to $74.00 and gave the company a "sector perform" rating in a research report on Wednesday, September 4th. Truist Financial upped their price objective on Gilead Sciences from $82.00 to $83.00 and gave the company a "hold" rating in a research report on Thursday, August 15th. Needham & Company LLC restated a "hold" rating on shares of Gilead Sciences in a research report on Thursday, August 15th. Finally, BMO Capital Markets upped their price objective on Gilead Sciences from $80.00 to $85.00 and gave the company an "outperform" rating in a research report on Friday, August 9th. Twelve research analysts have rated the stock with a hold rating, seven have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $82.06.

Gilead Sciences Trading Up 0.5 %

NASDAQ:GILD traded up $0.42 on Friday, hitting $82.81. 6,530,266 shares of the stock were exchanged, compared to its average volume of 7,168,032. The stock has a market cap of $103.10 billion, a PE ratio of 230.03, a PEG ratio of 2.80 and a beta of 0.18. The company has a current ratio of 1.14, a quick ratio of 0.95 and a debt-to-equity ratio of 1.18. The stock has a fifty day moving average of $75.48 and a 200-day moving average of $70.84. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $87.86.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its earnings results on Thursday, August 8th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.61 by $0.40. Gilead Sciences had a return on equity of 29.34% and a net margin of 3.79%. The business had revenue of $6.95 billion during the quarter, compared to analyst estimates of $6.64 billion. As a group, equities analysts expect that Gilead Sciences, Inc. will post 3.78 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, September 27th. Stockholders of record on Friday, September 13th will be paid a $0.77 dividend. The ex-dividend date is Friday, September 13th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 3.72%. Gilead Sciences's dividend payout ratio (DPR) is currently 855.56%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.